Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters

Cancer Gene Therapy

Volumn 21, Issue 4, 2014, Pages 171-178

  Dhar, D ^a   Toth, K ^a   Wold, W S M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYCLOPHOSPHAMIDE; NEUTRALIZING ANTIBODY; ONCOLYTIC ADENOVIRUS; UNCLASSIFIED DRUG; VRX 007; ALKYLATING AGENT; IMMUNOSUPPRESSIVE AGENT; ONCOLYTIC VIRUS;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE; HUMAN; HUMAN CELL; LYMPHOCYTE; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SYRIAN HAMSTER; TUMOR GROWTH; TUMOR IMMUNITY; ADENOVIRIDAE; ANIMAL; DRUG EFFECTS; GENE VECTOR; GENETICS; HAMSTER; IMMUNOLOGY; MESOCRICETUS; NEOPLASMS, EXPERIMENTAL; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE; VIROLOGY;

ADENOVIRIDAE; CRICETINAE; MESOCRICETUS AURATUS;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CRICETINAE; CYCLOPHOSPHAMIDE; GENETIC VECTORS; IMMUNOSUPPRESSIVE AGENTS; MESOCRICETUS; NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84897956577     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2014.13     Document Type: Article

References (32)

1. Wold WSM, Ison MG. Adenoviruses. In: Knipe DM, Howley PM editors. Fields Virology, 6th edition. Lippincott Williams &Wilkins: Philadelphia, PA, 2013 1732-1767.
2. Eager RM, Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther 2011; 18: 305-317.
3. Toth K, Dhar D, Wold WSM. Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opin Biol Ther 2010; 10: 353-368.
4. Pesonen S, Kangasniemi L, Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 2011; 8: 12-28.
5. Shi J, Zheng D. An update on gene therapy in China. Curr Opin Mol Ther 2009; 11: 547-553.
6. Ganesh S, Gonzalez EM, Idamakanti N, Abramova M, Vanroey M, Robinson M et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res 2007; 67: 4399-4407. [Erratum appears in Cancer Res. 2007;67(12):5998]. (Pubitemid 46815089)
7. McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 2006; 66: 2509-2513.
8. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12873-12878. (Pubitemid 44298654)
9. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips N, Wold WSM. Immunosuppression enhances oncolytic adenovirus replication and anti tumor efficacy in the Syrian hamster model. Mol Ther 2008; 16: 1665-1673.
10. Wold WS, Toth K. Chapter three-Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds. Adv Cancer Res 2012; 115: 69-92.
11. Dhar D, Toth K, Wold WSM. Syrian hamster tumor model to study oncolytic Ad5 based vectors. In: Kirn D, Liu TC, Thorne S editors. Oncolytic Viruses: Methods and Protocols. Humana Press: New York, 2012; 797: 53-63.
12. Young BA, Spencer JF, Ying B, Tollefson AE, Toth K, Wold WSM. The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors. Cancer Gene Ther 2013; 20: 521-530.
13. Dhar D, Spencer JF, Toth K, Wold WSM. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J Virol 2009; 83: 2130-2139.
14. Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 2008; 14: 259-269. (Pubitemid 351378003)
15. Hasegawa N, Abei M, Yokoyama KK, Fukuda K, Seo E, Kawashima R et al. Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters. Int J Cancer 2013; 133: 1479-1488.
16. Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999; 5: 881-887. (Pubitemid 29372413)
17. Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Parker WB, Sorscher EJ et al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 2007; 15: 1991-1997. (Pubitemid 350011739)
18. Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC et al. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 2009; 15: 2777-2788.
19. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999; 6: 1574-1583. (Pubitemid 29465516)
20. Doronin K, Toth K, Kuppuswamy M, Krajcsi P, Tollefson AE, Wold WSM. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 2003; 305: 378-387. (Pubitemid 36259672)
21. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WSM. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 1996; 70: 2296-2306. (Pubitemid 26087592)
22. Kuppuswamy M, Spencer JF, Doronin K, Tollefson AE, Wold WS, Toth K. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Ther 2005; 12: 1608-1617. (Pubitemid 41670351)
23. Toth K, Kuppuswamy M, Shashkova EV, Spencer JF, Wold WSM. A fully replicationcompetent adenovirus vector with enhanced oncolytic properties. Cancer Gene Ther 2010; 17: 761-770.
24. Dhar D, Spencer JF, Toth K, Wold WSM. Pre-existing immunity and passive immunity to Adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian Hamster Model. Mol Ther 2009; 17: 1724-1732.
25. Thomas MA, Spencer JF, Wold WSM. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. Methods Mol Med 2007; 130: 169-183.
26. Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1Battenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004; 10: 958-966.
27. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM et al. PhaseI-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 2005; 12: 437-445. (Pubitemid 40394296)
28. Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, Escutenaire S, Koski A et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic Adenovirus. Mol Ther 2011; 19: 1737-1746.
29. Lamfers ML, Fulci G, Gianni D, Tang Y, Kurozumi K, Kaur B et al. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther 2006; 14: 779-788. (Pubitemid 44743132)
30. Peng KW, Myers R, Greenslade A, Mader E, Greiner S, Federspiel MJ et al. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther 2013; 20: 255-261.
31. Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010; 18: 1874-1884.
32. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885. (Pubitemid 30644745)